282 related articles for article (PubMed ID: 15356143)
1. Delta-short consensus repeat 4-decay accelerating factor (DAF: CD55) inhibits complement-mediated cytolysis but not NK cell-mediated cytolysis.
Miyagawa S; Kubo T; Matsunami K; Kusama T; Beppu K; Nozaki H; Moritan T; Ahn C; Kim JY; Fukuta D; Shirakura R
J Immunol; 2004 Sep; 173(6):3945-52. PubMed ID: 15356143
[TBL] [Abstract][Full Text] [Related]
2. Effect of various forms of the C1 esterase inhibitor (C1-INH) and DAF on complement mediated xenogeneic cell lysis.
Fukuta D; Miyagawa S; Yamada M; Matsunami K; Kurihara T; Shirasu A; Hattori H; Shirakura R
Xenotransplantation; 2003 Mar; 10(2):132-41. PubMed ID: 12588646
[TBL] [Abstract][Full Text] [Related]
3. Effect of tandem forms of DAF(CD55) on complement-mediated xenogeneic cell lysis.
Miyagawa S; Fukuta D; Kitano E; Kobayashi C; Fumimoto Y; Shirasu A; Hattori H; Shirakura R; Fukuzawa M
Xenotransplantation; 2006 Sep; 13(5):433-9. PubMed ID: 16925667
[TBL] [Abstract][Full Text] [Related]
4. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor.
Coyne KE; Hall SE; Thompson S; Arce MA; Kinoshita T; Fujita T; Anstee DJ; Rosse W; Lublin DM
J Immunol; 1992 Nov; 149(9):2906-13. PubMed ID: 1383332
[TBL] [Abstract][Full Text] [Related]
5. C5b-8 step lysis of swine endothelial cells by human complement and functional feature of transfected CD59.
Miyagawa S; Mikata S; Shirakura R; Matsuda H; Nagasawa S; Terados A; Hatanaka M; Matsumoto M; Seya T
Scand J Immunol; 1996 Apr; 43(4):361-6. PubMed ID: 8668913
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of lymphocyte-mediated K562 cytotoxicity by antibodies against complement membrane cofactor protein (CD46) and decay-accelerating factor (CD55).
Seya T; Kojima A; Hara T; Hazeki K; Sugita Y; Akedo H
Immunobiology; 1991 Sep; 183(1-2):115-24. PubMed ID: 1718846
[TBL] [Abstract][Full Text] [Related]
7. Pigs express multiple forms of decay-accelerating factor (CD55), all of which contain only three short consensus repeats.
Pérez de la Lastra JM; Harris CL; Hinchliffe SJ; Holt DS; Rushmere NK; Morgan BP
J Immunol; 2000 Sep; 165(5):2563-73. PubMed ID: 10946283
[TBL] [Abstract][Full Text] [Related]
8. Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay.
Harris CL; Pettigrew DM; Lea SM; Morgan BP
J Immunol; 2007 Jan; 178(1):352-9. PubMed ID: 17182573
[TBL] [Abstract][Full Text] [Related]
9. Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP.
Huang J; Gou D; Zhen C; Jiang D; Mao X; Li W; Chen S; Cai C
FEMS Immunol Med Microbiol; 2001 Oct; 31(3):203-9. PubMed ID: 11720816
[TBL] [Abstract][Full Text] [Related]
10. Glycosyl phosphatidylinositol-linked blood group antigens and paroxysmal nocturnal hemoglobinuria.
Telen MJ
Transfus Clin Biol; 1995; 2(4):277-90. PubMed ID: 8542026
[TBL] [Abstract][Full Text] [Related]
11. Differential human serum-mediated neutralization of PERV released from pig cells transfected with variants of hDAF.
Okura E; Ishimaru A; Yamamoto A; Nakatsu S; Shirakura R; Okabe M; Sawa Y; Fukuzawa M; Okumura M; Miyagawa S
Xenotransplantation; 2008; 15(6):365-73. PubMed ID: 19152664
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human complement-dependent cell lysis by bovine aortic endothelial cells transfected with membrane-bound complement-regulatory factor (DAF and HRF20) gene using a retroviral vector.
Hayashi S; Isobe K; Emi N; Yokoyama I; Okada H; Nakashima I; Takagi H
Eur Surg Res; 1996; 28(6):440-6. PubMed ID: 8954321
[TBL] [Abstract][Full Text] [Related]
13. Test for ability of decay-accelerating factor (DAF, CD55) and CD59 to alleviate complement-mediated damage of xeno-erythrocytes.
Miyagawa S; Shirakura R; Matsumiya G; Nakata S; Matsuda H; Hatanaka M; Matsumoto M; Kitamura H; Seya T
Scand J Immunol; 1993 Jul; 38(1):37-44. PubMed ID: 7687071
[TBL] [Abstract][Full Text] [Related]
14. Effects of transfected complement regulatory proteins, MCP, DAF, and MCP/DAE hybrid, on complement-mediated swine endothelial cell lysis.
Miyagawa S; Shirakura R; Iwata K; Nakata S; Matsumiya G; Izutani H; Matsuda H; Terado A; Matsumoto M; Nagasawa S
Transplantation; 1994 Oct; 58(7):834-40. PubMed ID: 7524206
[TBL] [Abstract][Full Text] [Related]
15. A novel bifunctional chimeric complement inhibitor that regulates C3 convertase and formation of the membrane attack complex.
Fodor WL; Rollins SA; Guilmette ER; Setter E; Squinto SP
J Immunol; 1995 Nov; 155(9):4135-8. PubMed ID: 7594566
[TBL] [Abstract][Full Text] [Related]
16. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury.
Mason JC; Ahmed Z; Mankoff R; Lidington EA; Ahmad S; Bhatia V; Kinderlerer A; Randi AM; Haskard DO
Circ Res; 2002 Oct; 91(8):696-703. PubMed ID: 12386146
[TBL] [Abstract][Full Text] [Related]
17. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.
Varsano S; Rashkovsky L; Shapiro H; Ophir D; Mark-Bentankur T
Clin Exp Immunol; 1998 Aug; 113(2):173-82. PubMed ID: 9717965
[TBL] [Abstract][Full Text] [Related]
18. Molecular cloning of murine decay accelerating factor by immunoscreening.
Fukuoka Y; Yasui A; Okada N; Okada H
Int Immunol; 1996 Mar; 8(3):379-85. PubMed ID: 8671624
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the active sites in decay-accelerating factor.
Kuttner-Kondo LA; Mitchell L; Hourcade DE; Medof ME
J Immunol; 2001 Aug; 167(4):2164-71. PubMed ID: 11490001
[TBL] [Abstract][Full Text] [Related]
20. Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells.
Finberg RW; White W; Nicholson-Weller A
J Immunol; 1992 Sep; 149(6):2055-60. PubMed ID: 1381394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
